Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Ekvasis of Atorvastatin (Antorcin®) Treatment in Patients With Acute Cardiovascular Events (EKVASIS)

This study has been completed.
Information provided by (Responsible Party):
Elpen Pharmaceutical Co. Inc. Identifier:
First received: January 14, 2013
Last updated: August 18, 2014
Last verified: August 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2014
  Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)